Ropeginterferon alfa-2b

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ropeginterferon alfa-2b
DrugBank Accession Number
DB15119
Background

Ropeginterferon alfa-2b is under investigation in clinical trial NCT01949805 (Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera).

Type
Biotech
Groups
Approved, Investigational
Synonyms
  • Ropeginterferon alfa-2b
External IDs
  • AOP2014

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe metabolism of Acebutolol can be decreased when combined with Ropeginterferon alfa-2b.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Ropeginterferon alfa-2b.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Ropeginterferon alfa-2b.
AcyclovirThe metabolism of Acyclovir can be decreased when combined with Ropeginterferon alfa-2b.
AgomelatineThe metabolism of Agomelatine can be decreased when combined with Ropeginterferon alfa-2b.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Ropeginterferon alfa-2b.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Ropeginterferon alfa-2b.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Ropeginterferon alfa-2b.
AlosetronThe metabolism of Alosetron can be decreased when combined with Ropeginterferon alfa-2b.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ropeginterferon alfa-2b.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BesremiInjection, solution500 ?g/0.5mlSubcutaneousAop Orphan Pharmaceuticals Gmb H2020-12-16Not applicableEU flag
BesremiInjection, solution250 ?g/0.5mlSubcutaneousAop Orphan Pharmaceuticals Gmb H2020-12-16Not applicableEU flag
BesremiInjection, solution250 ?g/0.5mlSubcutaneousAop Orphan Pharmaceuticals Gmb H2021-03-03Not applicableEU flag

Categories

ATC Codes
L03AB15 — Ropeginterferon alfa-2b
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
981TME683S
CAS number
1335098-50-4

References

General References
  1. EMA Approved Products: Besremi (ropeginterferon alfa-2b ) solution for injection [Link]
Wikipedia
Ropeginterferon_alfa-2b

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedOtherPolycythemia Vera (PV)1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
3CompletedTreatmentPolycythemia Vera (PV)2
3RecruitingTreatmentEssential Thrombocythemia (ET)1
2Active Not RecruitingPreventionChronic Myeloid Leukemia in Remission1
2Active Not RecruitingTreatmentPolycythemia Vera (PV)2
2Enrolling by InvitationTreatmentPolycythemia Vera (PV)1
2RecruitingTreatmentAgnogenic Myeloid Metaplasia / Primary Myelofibrosis, Prefibrotic Stage1
2RecruitingTreatmentPrimary Myelofibrosis (PMF) / Secondary Myelofibrosis1
1CompletedTreatmentHealthy Subjects (HS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionSubcutaneous250 ?g/0.5ml
Injection, solutionSubcutaneous250 MCG/0.5ML
Injection, solutionSubcutaneous500 ?g/0.5ml
Injection, solutionSubcutaneous500 MCG/0.5ML
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Delaporte E, Renton KW: Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcriptional and post-transcriptional levels by conditions resulting in interferon-alpha/beta induction. Life Sci. 1997;60(10):787-96. doi: 10.1016/s0024-3205(97)00006-4. [Article]
  2. EMA Approved Products: Besremi (ropeginterferon alfa-2b ) solution for injection [Link]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. EMA Approved Products: Besremi (ropeginterferon alfa-2b ) solution for injection [Link]

Drug created on May 20, 2019 14:51 / Updated on April 21, 2021 06:21